A Novel Form of 4-1bbl Has Better Immunomodulatory Activity Than an Agonistic Anti-4-1bb Ab Without Ab-Associated Severe Toxicity

Vaccine - Netherlands
doi 10.1016/j.vaccine.2009.09.127
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

4-1bb Ligand (4-1bbl; TNFSF9; CD137L)

Science-Business eXchange
2012English

A Novel Form of 4-1bbl Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells

Cancer Research
Cancer ResearchOncology
2019English

AB Initio Study of (ZrB2) N, (N = 1-4)

International Journal for Research in Applied Science and Engineering Technology
2017English

Fc-Engineered Anti-4-1bb Antibodies Pack a One-Two Punch

Immunity
Infectious DiseasesAllergyImmunology
2018English

Forgotten “KANGRI” Related Severe Erythema Ab Igni

JMS SKIMS
2016English

A Novel Anti-Egfr mAb Ame55 With Lower Toxicity and Better Efficacy Than Cetuximab When Combined With Irinotecan

Journal of Immunology Research
MedicineAllergyImmunology
2019English

4-1bb Signaling Beyond T Cells

Cellular and Molecular Immunology
Infectious DiseasesMedicineAllergyImmunology
2011English

Mechanisms Involved in Synergistic Anticancer Effects of Anti-4-1bb and Cyclophosphamide Therapy

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Serum Concentrations of Soluble 4-1bb and 4-1bb Ligand Correlated With the Disease Severity in Rheumatoid Arthritis

Experimental & Molecular Medicine
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy